IRCT20181113041635N1已完成3 期
The effect of Combination Peg interferon –alpha to Tenofovir versus each one of the treatment modalities alone on Patients with HBeAg-negative: A randomized clinical trial
vice presidency for siences and technology , Iran national silences foundation0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Patients with the age of 18-65 years
- •Negative Hepatitis B e antigen at baseline
- •Quantifiable serum hepatitis B viral DNA load> 2000 IU/ml
- •At least six months from the initial diagnosis
- •Those with no history of receiving an antiviral drug
排除标准
- •Hepatitis C, D and HIV Viruses co-infection
- •Dialysis patients with renal impairment
- •Severe liver diseases
- •History of previous hepatitis B treatment (for at least 30 days)
- •Other liver comorbidities such as Autoimmune Hepatitis Hepatocellular Carcinoma, uncompensated cirrhosis
研究者
相似试验
未知
3 期
A study of peginterferon alfa-2a in combination with ribavirin in patients with chronic Hepatitis C.Chronic hepatitis CJPRN-jRCT2080220023Chugai Pharmaceutical Co., Ltd.
未知
2 期
A study of peginterferon alfa-2a in combination with ribavirin in chronic hepatitis C(CHC) patients with compensated liver cirrhosis(LC).CHC with compensated LCJPRN-jRCT2080220215Chugai Pharmaceutical Co., Ltd.
已完成
不适用
The effectiveness of peginterferon -alpha2a and the entecavir combination therapy for the chronic hepatitis B patientJPRN-UMIN000016275Kinki University School of Medicine50
已完成
3 期
Effect of Pegylated Interferon alfa-2a plus Adefovir in the treatment of chronic hepatitis B with genotype DChronic hepatitis B.Chronic viral hepatitis B without delta-agentIRCT138711201155N4Guilan University of Medical Sciences74
进行中（未招募）
不适用
Trial to compare the responses in two strata of patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia. Each patient will receive PEGASYS (Pegylated Interferon Alfa-2a) or Hydroxyurea (also known as Hydroxycarbamide). The treatment assigned will be chosen by chance.High Risk Polycythemia Vera or High Risk Essential ThrombocythemiaMedDRA version: 14.1Level: PTClassification code 10036057Term: Polycythaemia veraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019501-41-SECONSORZIO MARIO NEGRI SUD612